Michael Ulz
Stock Analyst at Morgan Stanley
(4.79)
# 108
Out of 5,148 analysts
103
Total ratings
67.24%
Success rate
41.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.47 | +326.17% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $92.29 | +33.28% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $332.92 | +22.55% | 13 | Jan 30, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $63.27 | +28.02% | 7 | Jan 7, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $46 → $50 | $15.62 | +220.10% | 3 | Dec 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.21 | +204.51% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $81.15 | +15.83% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $33.84 | +201.42% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $9.41 | +123.17% | 8 | Oct 9, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.44 | +359.56% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $3.32 | +562.65% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $12.49 | +132.19% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.86 | +418.13% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.48 | +372.97% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $13.45 | +100.74% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.94 | +2,018.87% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.01 | +798.20% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.53 | +1,792.86% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.53 | -33.77% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.09 | +230.03% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $23.39 | +242.03% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.37 | +4.38% | 3 | Jul 12, 2017 |
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.47
Upside: +326.17%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $92.29
Upside: +33.28%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $332.92
Upside: +22.55%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $63.27
Upside: +28.02%
Dyne Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $15.62
Upside: +220.10%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.21
Upside: +204.51%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $81.15
Upside: +15.83%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $33.84
Upside: +201.42%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $9.41
Upside: +123.17%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.44
Upside: +359.56%
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $3.32
Upside: +562.65%
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $12.49
Upside: +132.19%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.86
Upside: +418.13%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.48
Upside: +372.97%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $13.45
Upside: +100.74%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.94
Upside: +2,018.87%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $5.01
Upside: +798.20%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.53
Upside: +1,792.86%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.53
Upside: -33.77%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.09
Upside: +230.03%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $23.39
Upside: +242.03%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.37
Upside: +4.38%